Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
Near-term reductions in medical costs after prescription of reSET-O exceeded the amount needed to offset the cost of the product.
PreferredOne will provide broad patient access and reimbursement for reSET and reSET-O for people with substance use disorder and opioid use disorder.
Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of care alone.
The pilot program will enroll 250 patients with Substance Use Disorders (SUD) and offer each patient a 12-week course of reSET therapy.
The company will use the money to build and launch a portfolio of eFormulations, including reSET and reSET-O, for treating substance use disorder.
The company has offices in Boston and San Francisco, and is developing drug/software combination products to address a broad range of severe conditions.
The company makes prescription pharmaceutical-software combination products called eFormulations, which enhance the efficacy of pharmaceutical preparations.